Navigation Links
Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/18/2009

788, and working capital of $3,562,743, which the Company estimates will fund its operations for approximately the next seven months, as of December 31, 2008.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Comp
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
2. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
3. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
5. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
6. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
7. Senesco Technologies to Present at BIO 2008 Business Forum
8. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Belmont, MA (PRWEB) May 21, 2013 ... complete tracking to reporting eLearning solution using Tin ... report and dashboard tool. CLD is a leading ... biotech, and medical device companies worldwide. , ... tracking standard that helps learners and trainers more ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... 12 Two new white papers detailing,sterility ... download from,Microtest ( http://www.microtestlabs.com ). The white ... manufacturers and one which is specialized,for pharmaceutical ... with sterility testing and reviews different testing,methodologies. ...
... Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical ... drugs in the areas of women,s health and,cancer, announced today ... at A.G. Edwards, 2nd Annual Emerging Growth Conference in New,York. ... ET on Tuesday,September 18, 2007 at the New York Palace ...
... 12 Genstruct Inc., a,biotechnology company translating the ... announced today that its president and,CEO, Dr. Keith ... the Oncology,Clinical Trial Summit in Arlington, Va., September ... panel discussion focused on,"Enhancing Development and Commercial Value ...
Cached Biology Technology:Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Bionovo to Present at A.G. Edwards' 2nd Annual Emerging Growth Conference 2007 2Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
(Date:5/21/2013)... gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... resource assessment, market and policy developments, manufacturing and installation, ... and benefiting from its 2013 edition from a record ... 60 countries, more than 240 plenary and oral presentations, ...
(Date:5/21/2013)... The epigenetic modifications, which alter the way genes ... apparently be detected in the blood of pregnant ... way to foretell depression in the weeks after ... symptoms become debilitating. , The findings of the ... online in the journal Molecular Psychiatry . ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... times, cells sometimes resort to a form of self-cannibalism ... can have a down side, destroying the pancreas by ... swallows a portion of cytoplasm and ferries it to ... allowing hungry cells to recycle molecules, for example. However, ...
... known to be implicated in Crohn,s disease, a form of ... in the journal Nature Genetics , has identified a ... as providing surprising new links between the condition and other ... 1 in 500 and 1 in 1000 people within the ...
... throughout the world, resulting in large-scale ecosystem alteration and ... drought vary from year to year in severity and ... more severe conditions. Many modern varieties of potatoes ... cultivation in the cold, dry Andean Altiplano gave rise ...
Cached Biology News:Complexity of Crohn's disease revealed as 'gene' count tops 30 2Complexity of Crohn's disease revealed as 'gene' count tops 30 3Drought tolerance in potatoes 2Drought tolerance in potatoes 3
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Biology Products: